顺苯磺阿曲库铵结构式
|
常用名 | 顺苯磺阿曲库铵 | 英文名 | Cisatracurium Besylate |
|---|---|---|---|---|
| CAS号 | 96946-42-8 | 分子量 | 1243.479 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C65H82N2O18S2 | 熔点 | 90-93ºC | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS06 |
信号词 | Danger |
顺苯磺阿曲库铵用途Cisatracurium苯磺酸盐是非去极化神经肌肉阻断剂,能通过抑制神经肌肉的传递拮抗乙酰胆碱的效用。 |
| 中文名 | 苯磺顺阿曲库胺 |
|---|---|
| 英文名 | cisatracurium besylate |
| 中文别名 | 顺苯磺阿曲库铵 | (1R,1'R,2R,2'R)-2,2'-[1,5-戊二基双[氧(3-氧-3,1-丙二基)]]双[1-(3,4-二甲氧基苯基)甲基]-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉]二苯磺酸盐 | 顺苯磺阿曲库铵(1R | 顺苯阿曲库铵 |
| 英文别名 | 更多 |
| 描述 | Cisatracurium苯磺酸盐是非去极化神经肌肉阻断剂,能通过抑制神经肌肉的传递拮抗乙酰胆碱的效用。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 熔点 | 90-93ºC |
|---|---|
| 分子式 | C65H82N2O18S2 |
| 分子量 | 1243.479 |
| 精确质量 | 1242.500366 |
| PSA | 257.60000 |
| LogP | 11.32610 |
| InChIKey | XXZSQOVSEBAPGS-DONVQRBFSA-N |
| SMILES | COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)(O)c1ccccc1.O=S(=O)(O)c1ccccc1 |
| 外观性状 | 白色粉末 |
| 储存条件 | 室温,干燥 |
| 符号 |
GHS06 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H301-H319 |
| 警示性声明 | Missing Phrase - N15.00950417-P305 + P351 + P338 |
| 危险品运输编码 | UN 2811 6.1 / PGIII |
| 海关编码 | 2914509090 |
| 海关编码 | 2914509090 |
|---|---|
| 中文概述 | 2914509090 含其他含氧基的酮. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:5.5% 普通关税:30.0% |
| 申报要素 | 品名, 成分含量, 用途, 丙酮报明包装 |
| Summary | HS:2914509090 other ketones with other oxygen function VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:5.5% General tariff:30.0% |
|
The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Anesthesiology 82 , 1139-1145, (1995) Atracurium is a mixture of ten stereoisomers. 51W89, one of these isomers, is a potent nondepolarizing intermediate-duration neuromuscular blocking agent. Preclinical studies have shown 51W89 to be si... |
|
|
The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Anesthesiology 82 , 1131-1138, (1995) Atracurium consists of a mixture of ten stereoisomers. One of these isomers, 51W89, is a potent intermediate-acting nondepolarizing neuromuscular blocking agent. Its ED95 is 0.05 mg.kg-1 in patients r... |
|
|
Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat.
Anesthesiology 122(2) , 363-73, (2015) Rodent mesenchymal stem/stromal cells (MSCs) enhance repair after ventilator-induced lung injury (VILI). We wished to determine the therapeutic potential of human MSCs (hMSCs) in repairing the rodent ... |
|
实验名称:Liver toxicity in human assessed as induction of drug-induced liver injury by measuri...
来源:ChEMBL
靶标:Homo sapiens
External Id:CHEMBL4029349
|
|
实验名称:Liver toxicity in human assessed as induction of drug-induced liver injury by measuri...
来源:ChEMBL
靶标:Homo sapiens
External Id:CHEMBL4029350
|
|
实验名称:Dicer-mediated maturation of pre-microRNA
来源:Center for Chemical Genomics, University of Michigan
靶标:N/A
External Id:TargetID_659_CEMA
|
|
实验名称:S16 Schwann cell viability assay (CellTiter-Glo assay)
来源:NCGC
靶标:N/A
External Id:cmt-p4-fda-celltiter_regid
|
|
实验名称:Biochemical firefly luciferase enzyme assay for NPC
来源:NCGC
靶标:Luciferase [Photinus pyralis]
External Id:adst-fluc-km-fda-o1_regid
|
|
实验名称:S16 Schwann cell PMP22 intronic element firefly luciferase assay
来源:NCGC
靶标:peripheral myelin protein 22 [Rattus norvegicus]
External Id:cmt-p4-fluc-fda_regid
|
|
实验名称:qHTS for Inhibitors of Polymerase Kappa
来源:NCGC
靶标:DNA polymerase kappa [Homo sapiens]
External Id:PolK100
|
|
实验名称:MELAS cybrid survival enhancement under low glucose conditions
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School
靶标:N/A
External Id:HMS1419
|
|
实验名称:Inhibition of cell viability relative to arbidol control (inhibition index > 1 indica...
来源:ChEMBL
靶标:Severe acute respiratory syndrome coronavirus 2
External Id:CHEMBL4303819
|
| Cisatracurium |
| Cisatracurium bes (Cisatracuriumbesylate/Clotrimazole) |
| (1R,2R,1'R,2'R)-2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate |
| [1R-[1a,2a(1'R*,2'R*)]]-2,2'[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] Dibenzenesulfonate |
| bisbenzènesulfonate de (1R,2R,1'R,2'R)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-diméthoxybenzyl)-6,7-diméthoxy-2-méthyl-1,2,3,4-tétrahydroisoquinoléinium] |
| (1R,2R,1'R,2'R)-2,2'-{Pentan-1,5-diylbis[oxy(3-oxopropan-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisochinolinium]bisbenzolsulfonat |
| Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1R,2R,1'R,2'R)- benzenesulfonate (1:2) |
| Cis-AttacuriuM |
| (1R-cis,1'R-cis)-Atracurium besylate |
| cisatracurium besilate |
| Cisatracurium (besylate) |
| Cisatrcurium Besylate |
| UNII:Y78PS7MEDE |
| Cisatracurium besyla |
| 1R,1R'-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl) methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate |
| Cisatracurium besylate (USAN) |
| (1R,2R,1'R,2'R)-2,2'-{Pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate |
| Cisatracurium Besylate |
| (1R,1'R)-atracurium besylate |
| 1 kg-1.5kg |
| isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1R,2R,1'R,2'R)- bisbenzenesulfonate |
| (1R,1'R,2R,2'R) |
| Atracurium Impurity 1 |